作者: Tingyou Zhang , Yu Zhang , Lin Zhou , Shanshan Deng , Meijuan Huang
DOI: 10.1002/CAM4.3485
关键词:
摘要: BACKGROUND In this era of precision medicine, prognostic heterogeneity is an important feature patients with non-small cell lung cancer (NSCLC) brain metastases (BM). This multi-institutional study aimed to verify the applicability adjusted Lung-molGPA model for NSCLC BM in a Chinese cohort. METHODS retrospective included 1903 at three hospitals Southwest China. The performance was compared that DS-GPA terms estimating survival BM. RESULTS median OS patient cohort 27.0 months, and adenocarcinoma survived longer than non-adenocarcinoma (28.0 months vs 18.7 months, p < 0.001). more accurate predicting (C-index: 0.615 0.571), it not suitable (p = 0.286, 1.5-2.0 2.5-3.0; p = 0.410, 2.5-3.0 3.5-4.0). CONCLUSIONS better prognosis patients. However, failed estimate